Investment analysts at Morgan Stanley started coverage on shares of Gilead Sciences (NASDAQ:GILD) in a note issued to investors on Wednesday, StockRatingsNetwork.com reports. The firm set an “equal weight” rating on the stock. Gilead Sciences, Inc. (NASDAQ:GILD) shares after opening at $73.72 moved to $75.01 on last trade day and at the end of the day closed at $72.78. Company price to sales ratio in past twelve months was calculated as 9.97 and price to cash ratio as 52.37. Gilead Sciences, Inc. (NASDAQ:GILD) showed a negative weekly performance of -4.91%.
Shares of MannKind (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. This is an increase of approximately 105% compared to the average daily volume of 10,311 call options. MannKind Corporation (NASDAQ:MNKD) shares fell -7.24% in last trading session and ended the day on $5.38. MNKD return on equity ratio is recorded as 153.90% and its return on assets is -78.70%. MannKind Corporation (NASDAQ:MNKD) yearly performance is 61.56%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved down -1.16% in last trading session and was closed at $7.67, while trading in range of $7.56 – $8.00. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is 12.46%.
Brinson Patrick initiated coverage on shares of Rexahn Pharmaceuticals (NYSE:RNN) in a research note released on Monday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) weekly performance is -13.08%. On last trading day company shares ended up $1.13. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) distance from 50-day simple moving average (SMA50) is -5.17%. Analysts mean target price for the company is $2.33.
Leave a Reply